C. Solimeno

Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling.

C. Denkert, F. Marmé, P. Jank, 2022, The Journal of molecular diagnostics : JMD.

Abstract P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score

S. Cairo, A. Gutin, J. Lanchbury, 2015 .

Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer

A. Jazaeri, Ying Yuan, J. Lanchbury, 2021, Cancers.

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer

J. Reid, S. Darb-Esfahani, J. Lanchbury, 2018, British Journal of Cancer.

Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors

Z. Szallasi, I. Csabai, A. Eklund, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors

Z. Szallasi, I. Csabai, A. Eklund, 2018, bioRxiv.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)

N. Hansen, W. Gradishar, A. Gutin, 2015, Breast Cancer Research and Treatment.

Characteristics of homologous recombination deficiency (HRD) in paired primary and recurrent high-grade serous ovarian cancer (HGSOC)

J. Reid, S. Darb-Esfahani, J. Lanchbury, 2015 .

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

A. Richardson, A. Gutin, M. Goetz, 2023, Breast Cancer Research and Treatment.

Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.

G. Cancel-Tassin, E. Perrot, C. Solimeno, 2024, European urology oncology.